2-(叔丁基氨基)乙硫醇 | 5842-03-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(叔丁基氨基)乙硫醇
• 英文名称: 2-tert-Butylaminoethanthiol
• 英文别名: 2--ethanthiol, <2-Mercapto-ethyl>-tert.-butyl-amin；2-tert.-Butylamino-ethylmercaptan；2-(Tert-butylamino)ethanethiol
• CAS: 5842-03-5
• 化学式: C₆H₁₅NS
• mdl: MFCD19217233
• 分子量: 133.258
• InChiKey: MPIVGAOEKIJYJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  13
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(叔丁基氨基)乙硫醇 在 盐酸 、 potassium hexacyanoferrate(III) 作用下， 以 水 为溶剂， 反应 0.5h， 生成 tert-Butyl-[2-(2-tert-butylamino-ethyldisulfanyl)-ethyl]-amine
  参考文献：
  名称：

  Structure-activity relationships among di- and tetramine disulfides related to benextramine

  摘要：

  The synthesis and irreversible alpha-blocking activity in the rat vas deferens of a series of tetra- and diamine disulfides 2-38, structural analogues of benextramine (BHC), are described. All compounds containing a central cystamine moiety displayed an irreversible alpha-adrenergic blockade at concentrations ranging from 10(-4) to 6 X 10(-6)M. Potency was increased in cystamines N,N'-disubstituted with 6-aminohexyl groups, especially when the outer nitrogen atoms bear arylalkyl substituents or are enclosed in a ring. However, N,N,N',N'-tetrasubstituted cystamines were poor blockers. Structural specificity in the outer portion of the tetramine disulfide is low, since many types of substituents gave rise to potent alpha-blockers. Even replacement of the outer amines with nonbasic ethers or amides was observed to maintain irreversible alpha-blockade.

  DOI：

  10.1021/jm00390a011
• 作为产物：
  描述：

  环硫乙烷 、 叔丁胺 以 苯 为溶剂， 反应 3.0h， 生成 2-(叔丁基氨基)乙硫醇
  参考文献：
  名称：

  Structure-activity relationships among di- and tetramine disulfides related to benextramine

  摘要：

  The synthesis and irreversible alpha-blocking activity in the rat vas deferens of a series of tetra- and diamine disulfides 2-38, structural analogues of benextramine (BHC), are described. All compounds containing a central cystamine moiety displayed an irreversible alpha-adrenergic blockade at concentrations ranging from 10(-4) to 6 X 10(-6)M. Potency was increased in cystamines N,N'-disubstituted with 6-aminohexyl groups, especially when the outer nitrogen atoms bear arylalkyl substituents or are enclosed in a ring. However, N,N,N',N'-tetrasubstituted cystamines were poor blockers. Structural specificity in the outer portion of the tetramine disulfide is low, since many types of substituents gave rise to potent alpha-blockers. Even replacement of the outer amines with nonbasic ethers or amides was observed to maintain irreversible alpha-blockade.

  DOI：

  10.1021/jm00390a011

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE PAIN
  申请人：Kandula Mahesh

  公开号：US20150152081A1

  公开（公告）日：2015-06-04

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of severe pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain, generalized pain disorders, leukemia, cancer, chronic pain, chemotherapy induced pain, epilepsy, migraine, neuropathic pain, post herpetic neuralgia, neuralgia, pain, drug addiction, detoxification of drugs, Alzheimer's disease, multiple sclerosis, multiple sclerosis, restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, amyotrophic lateral sclerosis (ALS), convulsions, partial seizures, mood-stabilizing agent and bipolar disorder.

  该发明涉及公式I的化合物或其药用可接受盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I化合物的药物组合物，以及用于治疗严重疼痛的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这种组合物可用于治疗慢性疼痛、广泛性疼痛障碍、白血病、癌症、化疗引起的疼痛、癫痫、偏头痛、神经痛、带状疱疹后神经痛、神经痛、疼痛、药物成瘾、药物戒断、阿尔茨海默病、多发性硬化症、多发性硬化症、不宁腿综合征（RLS）、集束性头痛、抑郁症、纤维肌痛、肌萎缩侧索硬化症（ALS）、抽搐、部分性癫痫、情绪稳定剂和躁郁症的治疗。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS
  申请人：Kandula Mahesh

  公开号：US20150119452A1

  公开（公告）日：2015-04-30

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.

  本发明涉及化合物I的公式或其药用可接受的盐，以及其多型、溶剂合物、对映体、立体异构体和水合物。包含化合物I的有效量的药物组合物，以及用于治疗神经系统疾病的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂形式。这种组合物可以用于治疗纤维肌痛、抑郁症、神经病性疼痛、严重疼痛、慢性疼痛、全身疼痛、损伤、术后疼痛、骨关节炎、类风湿性关节炎、多发性硬化、脊髓损伤、偏头痛、HIV相关神经病性疼痛、带状疱疹后神经痛、糖尿病性神经病、癌症疼痛、纤维肌痛和腰背痛的治疗。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTONOMIC AND OTHER NEUROLOGICAL DISORDERS
  申请人：KANDULA Mahesh

  公开号：US20150210667A1

  公开（公告）日：2015-07-30

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of autonomic and other neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurogenic orthostatic hypotension (NOH), as well as NOH associated with multiple system atrophy (MSA), familial amyloid polyneuropathy (FAP), pure autonomic failure (PAF), and Parkinson's disease (PD), intradialytic hypotension (IDH) or hemodialysis-induced hypotension, hypotension associated with fibromyalgia syndrome (FMS) and chronic fatigue syndrome (CFS).

  该发明涉及公式I的化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括公式I化合物的有效量的药物组合物，以及用于治疗自主神经和其他神经系统疾病的方法可以制成口服、颊下、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂形式。这些组合物可用于治疗神经源性直立性低血压（NOH），以及与多系统萎缩（MSA）、家族性淀粉样多神经病（FAP）、纯自主神经功能衰竭（PAF）和帕金森病（PD）、透析期低血压（IDH）或血液透析诱发的低血压、与纤维肌痛综合症（FMS）和慢性疲劳综合症（CFS）相关的低血压。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION
  申请人：KANDULA Mahesh

  公开号：US20150148306A1

  公开（公告）日：2015-05-28

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of inflammation may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Type II diabetes, Type I diabetes, insulin resistance, cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, macular adema, arthritis, osteoarthritis, rheumatoid arthritis, inflammatory bowel syndrome, neudegeneration, Alzheimer's disease, Huntington's disease, Ulcerative colitis, Crohn's disease, Multiple Sclerosis, muscular dystropthy, metabolic syndrome, fatty liver, bone diseases, inflammatory diseases.

  该发明涉及公式I的化合物或其药用可接受的盐，以及其多晶形、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I化合物的药物组合物，以及用于治疗炎症的方法可以制成口服、颊部、直肠、局部、经皮、经粘膜、静脉、肠内、糖浆或注射剂。这些组合物可用于治疗II型糖尿病、I型糖尿病、胰岛素抵抗、心血管疾病、心律失常、动脉粥样硬化、冠状动脉疾病、高三酰甘油血症、脂质代谢异常、视网膜病变、肾病、神经病变、黄斑水肿、关节炎、骨关节炎、类风湿性关节炎、炎症性肠病、神经退行性疾病、阿尔茨海默病、亨廷顿病、溃疡性结肠炎、克罗恩病、多发性硬化症、肌肉萎缩症、代谢综合征、脂肪肝、骨疾病、炎症性疾病的治疗。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES
  申请人：Kandula Mahesh

  公开号：US20150152057A1

  公开（公告）日：2015-06-04

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, migraine, neuropathic pain, post herpetic neuralgia, pain, Creutzfeld-Jakob disease, Alzheimer's disease, multiple sclerosis, Batten disease, multiple sclerosis, Parkinson's disease (PD), restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, sexual dysfunction, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, autism, bipolar disorder and anxiety disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder, schizophrenia, neuropathic pain, seizures, bipolar disorder and mania.

  该发明涉及式I的化合物或其药用可接受的盐，以及其多晶形、溶剂合物、对映体、立体异构体和水合物。包括式I化合物有效量的药物组合物，以及用于治疗神经系统疾病的方法可以制备成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂形式。这些组合物可用于治疗癫痫、偏头痛、神经病性疼痛、带状疱疹后神经痛、疼痛、克雅氏病、阿尔茨海默病、多发性硬化症、巴顿病、多发性硬化症、帕金森病（PD）、不宁腿综合征（RLS）、集束性头痛、抑郁症、纤维肌痛、性功能障碍、肌萎缩侧索硬化（ALS）、阿尔茨海默病、自闭症、躁郁症和焦虑症、三叉神经痛、注意力缺陷多动障碍、精神分裂症、神经病性疼痛、癫痫、躁郁症和狂躁症的治疗。